Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.32 |
| ▸ | TUBB | P07437 | 4/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478147 | 0.75 | CYP1A2 (0.31) | CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4477931 | 0.71 | CSNK2A1 (0.34) | — | |
| SCHEMBL4463886 | 0.71 | ERN1 (0.33) | ERN1 | |
| SCHEMBL4694568 | 0.69 | ADORA2A (0.37) | ERN1FYNPLAUPPARG | |
| SCHEMBL4853131 | 0.67 | ABL1 (0.36) | CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL4459971 | 0.67 | CYP2A6 (0.38) | ERN1PDGFRBTUBB4ATUBBTUBA3C | |
| SCHEMBL6336378 | 0.67 | ERN1 (0.30) | ERN1 | |
| SCHEMBL7688531 | 0.67 | KDM4E (0.33) | — | |
| SCHEMBL27657345 | 0.67 | — | — | |
| SCHEMBL6334980 | 0.66 | ADORA2A (0.35) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CYP1A1 770/4885CYP1A2 628/4885CYP1B1 1237/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | CYP1A1 314/4885CYP1A2 175/4885CYP1B1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.